Immunization with hepatitis B vaccine is an effective measure for prevention and control of hepatitis B Virus (HBV) infection. Although lots of efforts to improve the effect of hepatitis B vaccine have been made, the function of human beta defensin 2 (hBD2) on hepatitis B vaccine keeps unclear. In this article, we report that hBD2 not only promoted the activation and maturation of immature dendritic cells (iDCs) by increasing MHC II and CD86 expression, but it also significantly upregulated the mRNA level of IL-6 and IL-12B in mouse bone marrow-derived dendritic cells. The serum concentrations of IFN-γ in mice stimulated with 300 ng hBD2 increased from 25.21 to 42.04 pg/mL, with a time extension from 4 to 12 h post-injection. During the process of three times immunization (1, 14, 28 days) with 3 μg hepatitis B vaccine combined with or without 300 ng hBD2 with a 2 week interval in BALB/c mice, the antibody against HBsAg (HBsAb) concentration in serum at every time point of observation in the combined group was statistically higher than the hepatitis B vaccine group. The serum concentration of IgG2a subclass HBsAb on the 14th day post last injection in the combined group was significantly higher than the hepatitis B vaccine group. Further, the splenic cells from the mice treated with both hBD2 and hepatitis B vaccine possessed a greater ability to produce a surface antigen of hepatitis B virus (HBsAg) specific IFN-γ than those treated with hepatitis B vaccine alone. The percentages of CD3+/CD4+ T cells and CD3+/CD8+ T lymphocytes in spleens from the mice treated with 300 ng hBD2 were statistically higher than the phosphate buffered saline group. These data suggest that hBD2 improves iDC maturation and the immune efficiency of hepatitis B vaccine in BALB/c mice.
Get full access to this article
View all access options for this article.
References
1.
AbdelAllahNH, AbdeltawabNF, BoseilaAA, et al.Chitosan and sodium alginate combinations are alternative, efficient, and safe natural adjuvant systems for hepatitis B vaccine in mouse model. Evid Based Complement Alternat Med, 2016; 2016:7659684.
2.
Al GhamdiSS, FallatahHI, FetyaniDM, et al.Long-term efficacy of the hepatitis B vaccine in a high-risk group. J Med Virol, 2013; 85:1518–1522.
3.
AuvynetC, and RosensteinY. Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J, 2009; 276:6497–6508.
4.
BhatS, SongYH, LawyerC, et al.Modulation of the complement system by human β-defensin 2. J Burns Wounds, 2007; 10:e10.
5.
BianG, ChengY, WangZ, et al.Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses. Vaccine, 2010; 28:187–194.
6.
BiragynA, RuffiniPA, LeiferCA, et al.Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science, 2002; 298:1025–1029.
7.
BoniottoM, JordanWJ, EskdaleJ, et al.Human β-defensin 2 induces a vigorous cytokine response in peripheral blood mononuclear cells. Antimicrob Agents Chemother, 2006; 50:1433–1441.
8.
ChlabiczS, GrzeszczukA, and ŁapińskiTW. Hepatitis B vaccine immunogenicity in patients with chronic HCV infection atone year follow-up: the effect of interferon-alpha therapy. Med Sci Monit, 2002; 8:CR379–CR383.
9.
ChuchuN, PatelB, SebastianB, et al.The aluminum content of infant formulas remains too high. BMC Pediatr, 2013; 13:162.
10.
CorkinsMR. Aluminum effects in infants and children. Pediatrics, 2019; 144:e20193148.
11.
DeligneC, MetidjiA, FridmanWH, et al.Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia, 2015; 29:947–957.
12.
Di BisceglieAM, KingWC, Lisker-MelmanM, et al.Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. J Viral Hepat, 2019; 26:856–865.
13.
FabriziF, DixitV, MessaP, et al.Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials. Vaccine, 2012; 30:2295–2300.
14.
FakharzadehS, KalanakyS, HafiziM, et al.The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine. Vaccine, 2013; 31:2591–2597.
15.
GisbertJP, VillagrasaJR, Rodríguez-NogueirasA, et al.Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol, 2012; 107:1460–1466.
16.
GrzegorzewskaAE. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Rev Vaccines, 2014; 13:1317–1326.
17.
HaradaY, Okada-NakanishiY, UedaY, et al.Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells. Sci Rep, 2011; 1:174.
18.
HeffernanMH, ZaharoffDA, FallonJK, et al.In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials, 2011; 32:926–932.
19.
HyerRN, and JanssenRS. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60–70 years. Vaccine, 2019; 37:5854–5861.
20.
IgbokweIO, IgwenaguE, and IgbokweNA. Aluminium toxicosis: a review of toxic actions and effects. Interdiscip Toxicol, 2019; 12:45–70.
21.
JiaHP, WowkSA, SchutteBC, et al.A novel murine beta-defensin expressed in tongue, esophagus, and trachea. J Biol Chem, 2000; 275:33314–33320.
22.
KandaN, KamataM, TadaY, et al.Human-defensin-2 enhances IFN- and IL-10 production and suppresses IL-17 production in T cells. J Leukoc Biol, 2011; 89:935–944.
23.
KaoHH, ChenKS, LinCL, et al.Utilization of signal-to-cutoff ratio of hepatitis C virus antibody assay in predicting HCV viremia among hemodialysis patients. Nephron, 2015; 130:127–133.
24.
KatoY, OnishiH, and MachidaY. Application of chitin and chitosan derivatives in the pharmaceutical field. Curr Pharm Biotechnol, 2003; 4:303–309.
25.
KimJ, YangYL, JangSH, et al.Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity. Virol J, 2018; 15:124.
26.
KimJ, YangYL, and JangYS. Human β-defensin 2 is involved in CCR2-mediated Nod2 signal transduction, leading to activation of the innate immune response in macrophages. Immunobiology, 2019; 224:502–510.
27.
KomatsuH, InuiA, FujisawaT, et al.Transmission route and genotype of chronic hepatitis B virus infection in children in Japan between 1976 and 2010: a retrospective, multicenter study. Hepatol Res, 2014; 45:629–637.
28.
KwissaM, LindbladEB, SchirmbeckR, et al.Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response. J Mol Med (Berl), 2003; 81:502–510.
29.
Mackenzie-DyckS, Attah-PokuS, JuillardV, et al.The synthetic peptides bovine enteric-defensin (EBD), bovine neutrophil-defensin (BNBD) 9 and BNBD 3 are chemotactic for immature bovine dendritic cells. Vet Immunol Immunopathol, 2011; 143:87–107.
30.
MorgeraF, PacorS, CreattiL, et al.Effects on antigen-presenting cells of short-term interaction with the human host defence peptide β-defensin 2. Biochem J, 2011; 436:537–546.
31.
MucciI, LegitimoA, CompagninoM, et al.The methodological approach for the generation of human dendritic cells from monocytes affects the maturation state of the resultant dendritic cells. Biologicals, 2009; 37:288–296.
32.
MühlemannB, JonesTC, DamgaardPB, et al.Ancient hepatitis B viruses from the Bronze Age to the Medieval period. Nature, 2018; 557:418–423.
33.
MutwaPR, BoerKR, RusineJB, et al.Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda. Pediatr Infect Dis J, 2013; 32:246–251.
34.
NiyonsabaF, HirataM, OgawaH, et al.Epithelial cell-derived antibacterial peptides human β-defensins and cathelicidin: multifunctional activities on mast cells. Curr Drug Targets Inflamm Allergy, 2003; 2:224–231
35.
NiyonsabaF, OgawaH, and NagaokaI. Human β-defensin-2 functions as a chemotactic agent for tumour necrosis factor-α-treated human neutrophils. Immunology, 2004; 111:273–281
36.
PetrovskyN. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf, 2015; 38:1059–1074,
37.
PriestND. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. J Environ Monit, 2004; 6:375–403.
38.
QiaoYP, SuM, SongY, et al.Outcomes of the national programme on prevention of mother-to-child transmission of hepatitis B virus in China, 2016–2017. Infect Dis Poverty, 2019; 8:65
39.
RöhrlJ, YangD, OppenheimJJ, et al.Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J Immunol, 2010; 184:6688–6694.
40.
SchenkelJM, FraserKA, BeuraLK, et al.Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science, 2014; 346:98–101.
41.
ShahR, HassettKJ, and BritoLA. Overview of Vaccine Adjuvants: Introduction, History, and Current Status. In: Christopher B. Fox, ed. Vaccine Adjuvants: Methods and Protocols, ebook. New York: Humana Press, 2017.
42.
ShawCA, LiD, and TomljenovicL. Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy?. Immunotherapy, 2014; 6:1055–1071.
43.
SheY, WangN, ChenC, et al.Effects of aluminum on immune functions of cultured splenic T and B lymphocytes in rats. Biol Trace Elem Res, 2012; 147:246–250.
44.
SonYI, EgawaS, TatsumiT, et al.A novel bulk-culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods, 2002; 262:145–157.
45.
SoruriA, GrigatJ, ForssmannU, et al.beta-Defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur J Immunol, 2007; 37:2474–2486.
46.
SunT, LuoY, WangM, et al.Recombinant oncolytic vaccinia viruses expressing human β-defensin 2 enhance anti-tumor immunity. Mol Ther Oncolytics, 2019; 13:49–57.
47.
TecleT, TripathiS, and HartshornKL. Review: defensins and cathelicidins in lung immunity. Innate Immun, 2010; 16:151–159.
48.
UrganciN, and KalyoncuD. Immunogenecity of hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr, 2013; 56:412–415.
49.
VemulaSV, AmenO, KatzJM, et al.Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Res, 2013; 178:398–403.
50.
VemulaSV, PandeyA, SinghN, et al.Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice. Virus Res, 2013; 177:55–61.
51.
VongsaRA, ZimmermanNP, and DwinellMB. CCR6 regulation of the actin cytoskeleton orchestrates human β defensin-2- and CCL20-mediated restitution of colonic epithelial cells. J Biol Chem, 2009; 284:10034–10045.
52.
WangP, XueY, HanY, et al.The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science, 2014; 344:310–313.
53.
WangZ, and LiYF. Immunotoxic effects of aluminium on chicken splenic lymphocyte cultured in vitro. Asian J Ecotoxicol, 2008; 3:174–177.
54.
WeiXM, LuJP, FangQH, et al.Immunotoxicology of AlCl3 on the human T-lymphocyte cultivated in vitro. Chin J Prev Med, 2001; 35:213–214.
55.
WHO: Global Newsroom for the detail of Hepatitis B.www.who.int/news-room/fact-sheets/detail/hepatitis-b, website report on 18th July 2019. (accessed February16, 2020)
56.
YangD, ChertovO, BykovskaiaSN, et al.β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science, 1999; 286:525–528
57.
YangX, XuF, ZhuangC, et al.Effects of corticosterone on immune functions of cultured rat splenic lymphocytes exposed to aluminum trichloride. Biol Trace Elem Res, 2016; 173:399–404.
58.
YuH, ZhangJ, JiQ, et al.Melatonin alleviates aluminium chloride-induced immunotoxicity by inhibiting oxidative stress and apoptosis associated with the activation of Nrf2 signaling pathway. Ecotoxicol Environ Saf, 2019; 173:131–141.
59.
YuanXW, WangJX, ChengMQ, et al.Mouse β-defensin-14 for inducing the maturation of dendritic cells. Int Immunopharmacol, 2018; 55:133–141.
60.
ZhaoJ, WangZ, ChenX, et al.Effects of intravesical liposome-mediated human beta-defensin-2 gene transfection in a mouse urinary tract infection model. Microbiol Immunol, 2011; 55:217–223.
61.
ZhaoYL, HanBH, ZhangXJ, et al.Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination. BMC Infect Dis, 2019; 19:482.
62.
ZhaoYL, PanaLL, HaoZY, et al.Immune response to different types of hepatitis B vaccine booster doses 2–32 years after the primary immunization schedule and its influencing factors. Int J Infect Dis, 2020; 93:62–67.
63.
ZhuY, LiY, MiaoL, et al.Immunotoxicity of aluminum. Chemosphere, 2014; 104:1–6.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
